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BACKGROUND: To characterise recurrence patterns and survival following pathologic complete response (pCR) in patients who
received preoperative therapy for localised gastric or gastrooesophageal junction (GEJ) adenocarcinoma.
METHODS: A retrospective review of a prospective database identified patients with pCR after preoperative chemotherapy for gastric
or preoperative chemoradiation for GEJ (Siewert II/III) adenocarcinoma. Recurrence patterns, overall survival, recurrence-free
survival, and disease-specific survival were analysed.
RESULTS: From 1985 to 2009, 714 patients received preoperative therapy for localised gastric/GEJ adenocarcinoma, and 609 (85%)
underwent a subsequent R0 resection. There were 60 patients (8.4%) with a pCR. Median follow-up was 46 months. Recurrence at 5
years was significantly lower for pCR vs non-pCR patients (27% and 51%, respectively, P¼0.01). The probability of recurrence for
patients with pCR was similar to non-pCR patients with pathologic stage I or II disease. Although the overall pattern of local/regional
(LR) vs distant recurrence was comparable (43% LR vs 57% distant) between pCR and non-pCR groups, there was a significantly
higher incidence of central nervous system (CNS) first recurrences in pCR patients (36 vs 4%, P¼0.01).
CONCLUSION: Patients with gastric or GEJ adenocarcinoma who achieve a pCR following preoperative therapy still have a significant
risk of recurrence and cancer-specific death following resection. One third of the recurrences in the pCR group were symptomatic
CNS recurrences. Increased awareness of the risk of CNS metastases and selective brain imaging in patients who achieve a pCR
following preoperative therapy for gastric/GEJ adenocarcinoma is warranted.
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Together, gastric and oesophageal adenocarcinoma are the second
most common malignancies of the gastrointestinal tract in the
United States and worldwide (Kamangar et al, 2006; Jemal et al,
2010). The US age-adjusted incidence and mortality of gastric/
gastrooesophageal junction (GEJ) adenocarcinoma is 7.3 and 5.04
per 100000 persons, respectively, and the incidence of gastric
cancer is rising in the United States in the young age bracket
(Anderson et al, 2010; Shah and Ajani, 2010). The majority of
patients presenting with resectable gastric/GEJ adenocarcinoma
will have locally advanced disease (defined as the penetration of
the subserosa by the primary tumour (T3), regional nodal
involvement (Nþ), or both (Edge et al, 2010)) for which the
chance of cure with surgery alone is poor (Hundahl et al, 2000; Wu
et al, 2009; Anderson et al, 2010). For these locally advanced cases,
several random assignment studies have established additional
therapy as the standard of care, including perioperative chemo-
therapy with or without radiation therapy (RT) (Cunningham et al,
2006; Stahl et al, 2009), or postoperative chemoradiation
(Macdonald et al, 2001), highlighting the importance of multi-
disciplinary care for these patients.
It is well established that pathologic complete response (pCR)
following preoperative therapy is associated with improved
survival in several malignancies, including breast adenocarcinoma
after preoperative chemotherapy±RT (Wolmark et al, 2001;
Symmans et al, 2007; Adams et al, 2010; Chavez-Macgregor et al,
2010), oesophageal cancer after preoperative chemoradiotherapy
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s(Berger et al, 2005; Rohatgi et al, 2005; Chao et al, 2009; Donahue
et al, 2009; Park et al, 2010), lung cancer after preoperative
chemoradiotherapy (Mamon et al, 2005; Chen et al, 2007), and
rectal cancer after preoperative chemoradiotherapy (Maas et al,
2010). Notably, the 15–27% rate of pCR after chemoradiotherapy
in rectal cancer (Pucciarelli et al, 2004) has led some groups to
omit surgery and undertake intensive follow-up in select patients
who achieve a clinical complete response with no detectable
residual tumour after chemoradiotherapy (Habr-Gama et al, 2004).
The timing and pattern of recurrence and overall patient
survival in patients with gastric/GEJ adenocarcinoma achieving a
pCR after preoperative multimodality treatment is not well
characterised, with the current description limited to a single
series of 24 patients with gastric cancer who achieved a pCR
following chemoradiation (Reed et al, 2008). Herein, we report our
experience in patients with gastric/GEJ adenocarcinoma who
received preoperative chemotherapy±RT followed by complete
(R0) resection and achieved a pCR. We compare their survival and
recurrence to similarly treated patients who did not achieve a pCR.
PATIENTS AND METHODS
Patients and pretreatment evaluation
Patients with gastric/GEJ adenocarcinoma who received preopera-
tive therapy were identified from a prospective surgical database at
Memorial Sloan-Kettering Cancer Center (MSKCC) from 1985 to
2009. The MSKCC Institutional Review Board approved the study
design. Patients with a diagnosis of distal oesophageal carcinoma
(Siewert I) were excluded.
Pretreatment evaluation usually consisted of a computed
tomography (CT) scan of the abdomen and pelvis, endoscopic
ultrasound (EUS), diagnostic laparoscopy with cytologic washings,
and selective use of positron emission tomography (PET). We
collected patient demographics including age, gender, race, and
body mass index; preoperative tumour characteristics including
tumour location, pretreatment EUS T-stage, and tumour histology;
and preoperative chemotherapy regimen and use of RT.
Treatment
Preoperative chemotherapy was administered in the outpatient
setting and was grouped into: 5-fluorouracil (5-FU) and platinum-
based regimens (including epirubicinþcisplatin or oxaliplatinþ
5-FU or capecitabine (ECF/ECX/EOX/EOF), and cisplatin/5-FU),
platinum-based regimens (including cisplatin/CPT11), taxane-
based regimens (including taxaneþCPT11±5-FU), and other
regimens (including 5-FUþdoxorubicinþmethotrexate (FAMTX),
mitomycin C, and doxorubicin).
Preoperative radiation was delivered as multifield, external-
beam megavoltage radiation using high-energy linear accelerators
(6 or 15MV). Treatment generally included five daily fractions of
1.8Gy per week over a 5.5-week course with a total radiation dose
of 50.4Gy. The superior field border extended B5cm cranial to
the tumour, and the inferior border extended caudally to include
the coeliac lymph node (LN) region. The anterior, posterior, and
lateral field borders were B2cm beyond the tumour, as defined by
pretreatment imaging. The locoregional LNs were included in the
radiation field.
After preoperative treatment, patients underwent gastrectomy or
oesophagogastrectomy with two-field (for oesophagogastrectomy)
or D2 (for gastrectomy) lymphadenectomy and splenic preserva-
tion whenever possible. A curative (R0) resection was defined as
the removal of all visible disease and associated nodal basins with
negative microscopic surgical margins on final pathologic review.
Pathologic staging is reported according to the American Joint
Committee on Cancer staging guidelines (7th edn) for gastric
adenocarcinoma (Edge et al, 2010). Surgical treatment character-
istics collected included operative and pathologic details, including
extent of gastrectomy/oesophagogastrectomy, type of LN dissec-
tion, and resected specimen pathologic analysis (T-stage, N-stage,
number of LN examined, and pathologic treatment effect).
Follow-up laboratory and imaging studies and additional
postoperative treatment were at the discretion of the treating
physician(s) or as directed by a patient-enrolled protocol (Kelsen
et al, 1992, 1997; Bains et al, 2002; Brenner et al, 2004, 2006;
Anderson et al, 2007; Schwartz et al, 2009). Patients were generally
followed every 2–3 months for the first 2 years, followed by every
6–12 months thereafter. Recurrence was confirmed radiographi-
cally and/or pathologically and described as local/regional
(including peritoneal) or distant. Date of recurrence was defined
as the first notation in the medical record indicating the
recurrence. Disease status at last follow-up and cause of death
were determined by the medical record, death certificates, and
follow-up correspondence.
Pathology
Pathologic complete response was defined as fibrosis or fibroin-
flammation within an entirely submitted and evaluated gross
lesion without microscopic evidence of carcinoma, and histologi-
cally negative nodes. Non-pCR was defined as any evidence of
viable carcinoma, either at the primary site or in the resected
regional LN. The pathologic stage of residual carcinoma in the
non-pCR group was based on the deepest focus of viable malignant
epithelium in the gastric and oesophageal wall and/or any
carcinoma found in the LN analysis. Pathologic treatment effect
was analysed and quantified on a graded, per cent scale as
previously described (Mansour et al, 2007). Positive LNs were
defined as the presence of any viable tumour cells within LNs.
Statistical analysis
Statistical analysis was performed using the R package, version
2.10 (http://www.r-project.org). Patient, tumour, and treatment
variables were compared between the pCR and non-pCR groups
using the w
2 and Wilcoxon rank sum test with continuity
correction for categorical and continuous variables, respectively.
Recurrence-free survival (RFS) was compared between the pCR
and non-pCR groups using the log-rank test. Recurrence location
was compared using the w
2 test. Kaplan–Meier methods were used
to estimate overall survival (OS), disease-specific survival (DSS),
and RFS probability between pCR and non-pCR groups and
compared using the log-rank test (Kaplan and Meier, 1958). Death
without a recurrence was considered as a competing cause of
failure (Prentice et al, 1978; Satagopan et al, 2004). Estimated
cumulative incidence of recurrence was performed using the
subdistribution method and compared using Gray’s test (Gray,
1988).
RESULTS
From 1985 to 2009, 2676 patients underwent surgical treatment for
gastric or GEJ (Siewert II/III) adenocarcinoma at MKSCC. In all,
714 of these patients (27%) received preoperative chemothera-
py±RT. One hundred and five patients (15%) had either positive
surgical margins after resection (64 patients, 9%) or presence of
metastatic disease at surgical exploration/resection (41 patients,
6%) and were excluded from subsequent analysis. The final study
population was 609 patients with gastric/GEJ adenocarcinoma
treated with preoperative therapy (280 (46%) chemoradiotherapy,
329 (54%) chemotherapy alone) followed by complete (R0)
resection. Sixty patients (8.4% of all preoperative treatment
patients; 10% of preoperative treatment patients who underwent
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and are defined as the pCR group, and the remainder (n¼549,
90% of all preoperative treatment patients who underwent R0
resection) had residual evidence of malignancy and are defined as
the non-pCR group (Figure 1).
Table 1 lists the patient characteristics of the pCR and non-pCR
patients. There were no differences between the pCR and non-pCR
groups with respect to patient age, race, pretreatment EUS T-stage,
or histology (Lauren or differentiation). Most patients had
advanced T-stage tumours (X80% T3 for both pCR and non-
pCR patients). Forty-seven patients who received chemoradiation
(17%) achieved a pCR, and 12 (26%) of these patients recurred.
Thirteen patients who received chemotherapy alone (4%) achieved
a pCR, and 2 (17%) of these patients recurred. Patients who
received taxane-based therapy more commonly also received
concurrent radiotherapy and therefore more commonly achieved
a pCR.
Table 2 lists the pathologic T- and N-stages and extent of
surgical nodal resection. There were no differences in the extent of
LN dissection (D1, D2, or D3) between the pCR and non-pCR
groups. The non-pCR patients had a mean of 3.0 (range 1–8)
positive LNs and a mean pathologic treatment effect of 45% (range
10–95). The pCR group had a higher mean number of LNs
examined (29 vs 23), P¼0.04.
Median follow-up for all surviving patients was 46 months
(interquartile range¼16–90). Of the 549 patients with a non-pCR,
153 (28%) received postoperative (adjuvant) chemotherapy, and
of the 60 patients with a pCR, one patient received additional
postoperative chemotherapy. Overall survival, DSS, and RFS was
significantly greater in the pCR group compared with the non-pCR
group (Figure 2). The timing and pattern of recurrences are
summarised in Table 3. For patients achieving a pCR, there was no
difference in recurrence between patients who received chemor-
adiotherapy vs chemotherapy alone (26% and 15%, respectively,
P¼0.2). While the non-pCR group had a higher risk of recurrence
at 1, 3, and 5 years (5-year recurrence¼27 vs 51% for pCR and
non-pCR, respectively, P¼0.02), the pattern of recurrence was
similar. There was no difference in the distribution of local/
regional vs distant recurrences (43% vs 57%, respectively) between
pCR and non-pCR groups. However, we did observe a significantly
higher incidence of first recurrences in the central nervous system
(CNS) in pCR (36%) compared with non-pCR (4%) patients
(P¼0.01). All of the patients with a CNS recurrence in the pCR
group presented symptomatically (four with seizures and one with
localising neurologic symptoms), and similarly 8 of the 10 patients
(4%) in the non-pCR group who initially recurred in the CNS
presented symptomatically (seven with seizures and one with
localising neurologic symptoms).
Figure 3 summarises the probability of recurrence by final
pathologic stage when treating death from other causes as a
competing risk. When compared with pCR patients, the prob-
ability of recurrence is significantly higher only for pathologically
stage III (pIII) non-pCR patients (5-year CI of recurrence¼74 vs
27%, Po0.001). Among the pIII patients, although the majority
were stage III by virtue of residual nodal involvement, the three
node negative (i.e., T4N0) pIII patients also had a high risk
of recurrence, each one developing recurrence within 1 year of
resection. There is no significant difference in the probability of
2676 Patients treated surgically for
gastric/GEJ adenocarcinoma
between 1985 and 2009
714 Patients (27%) received
preoperative chemotherapy
± radiation therapy
105 Patients (15%) excluded
￿  Positive surgical margin (n=64)
￿  Metastatic disease (n=41)
609 Patients (23%) underwent R0
resection with no evidence of
metastatic disease
549 Patients (90%) with residual
tumour on final pathology (non-pCR)
60 Patients (10%) with no residual
tumour on final pathology (pCR)
Figure 1 Patient study group CONSORT diagram.
Table 1 Patient, tumour, and preoperative treatment variables in
patients undergoing preoperative chemotherapy±radiation therapy for
gastric and gastrooesophageal junction adenocarcinoma, followed by R0
resection
Number (%)
Variable
Non-pCR
patients
(n¼549)
pCR
patients
(n¼60) P-value
a
Age (median, IQR) 62 (54–69) 64 (56–69) 0.18
b
Preoperative BMI (median, IQR) 27 (24–30) 28 (25–32) 0.04
b
Gender
Male 403 (73) 52 (87) 0.02
Female 146 (27) 8 (13)
Race
Caucasian 487 (89) 57 (95)
African-American 24 (4) 1 (2) 0.64
Asian/Pacific Islander 31 (6) 2 (3)
Other/unknown 7 (1) 0 (0)
Tumour location
GEJ 312 (57) 47 (78)
Gastric, proximal 74 (13) 6 (10)
Gastric, body 71 (13) 4 (7) 0.02
Gastric, distal 85 (15) 3 (5)
Gastric, diffuse 7 (1) 0 (0)
Pretreatment EUS T-stage
T1 4 (1) 0 (0)
T2 72 (13) 10 (17)
T3 447 (81) 50 (83) 0.43
T4 15 (3) 0 (0)
Not performed 11 (2) 0 (0)
Histology – Lauren classification
Diffuse 169 (31) 19 (32)
Intestinal 333 (61) 39 (65) 0.62
Mixed 47 (9) 2 (3)
Histology – differentiation
Well 12 (2) 3 (5)
Moderate 207 (38) 14 (23) 0.25
Poor 330 (60) 43 (72)
Preoperative chemotherapy regimen
5-FU and platinum based 221 (39) 23 (34)
Platinum based 157 (27) 15 (22) 0.0007
Taxane based 130 (23) 28 (41)
Other 65 (11) 2 (3)
Preoperative radiation treatment
Yes 233 (42) 47 (78) o0.0001
Abbreviations: 5-FU¼5-fluorouracil; BMI¼body mass index; GEJ¼gastrooesophageal
junction; IQR¼interquartile range; pCR¼pathologic complete response; EUS¼endo-
scopic ultrasound.
aw
2 text, except where otherwise noted by ‘b’.
bWilcoxon rank sum
test with continuity correction. Bold values indicate significant differences.
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non-pCR patients (5-year CI of recurrence¼39% and 25%,
respectively, P¼0.49 for pCR vs non-pCR stage I and P¼0.36
for pCR vs non-pCR stage II).
Table 4 provides clinical characteristics of those patients with
pCR who developed recurrence (n¼14, 23%). Five patients (36% of
pCR recurrences; 8% of all pCR patients) developed CNS recurrence
as their first site of recurrence, with a mean time to recurrence of
12.6±7.7 months (range 5–24 months). Treatment after CNS
recurrence consisted of whole brain RT in two patients, surgery
(craniotomy) in one patient, and no treatment in two patients. All
five pCR patients with CNS recurrences died of their disease, with a
mean time from recurrence to death of 9.6 months (range¼2–26
months). Of note, 6 of the 14 pCR patients that recurred (43%) had
local/regional recurrence (anastomotic or regional nodal), all of
whom received preoperative chemoradiation.
DISCUSSION
In the past 10 years, results of several randomised controlled trials
have established multimodality therapy as the standard of care for
locally advanced gastric/GEJ adenocarcinoma (Macdonald et al,
2001; Cunningham et al, 2006; Stahl et al, 2009; Schuhmacher
et al, 2010). Reflective of the multidisciplinary approach to locally
advanced gastric and GEJ adenocarcinoma, we describe the
outcome of patients who received preoperative chemotherapy or
chemoradiation followed by complete surgical resection and who
achieved a pCR to preoperative therapy. We found a 10% pCR rate
in patients with gastric/GEJ adenocarcinoma treated with pre-
operative chemotherapy±RT followed by R0 resection (17% with
prior chemoradiation and 4% with chemotherapy alone).
Importantly, despite achieving a pCR with preoperative therapy
and independent of type of therapy, the risk of recurrence remains
significant; indistinguishable from patients who were downstaged
to pathologic stage I or II following preoperative therapy. There is
a substantial rate of CNS first recurrences (8% of all pCR patients
and 36% of the pCR patients who developed a recurrence) in
this cohort of patients, with each CNS recurrence presenting with
life-threatening neurologic symptoms.
Table 2 Pathologic variables in patients undergoing preoperative
chemotherapy±radiation therapy for gastric and gastrooesophageal
junction adenocarcinoma, followed by R0 resection
Number (%)
Variable
Non-pCR
patients
(n¼549)
pCR
patients
(n¼60) P-value
pT stage
a
T0
b 11 (2) 60 (100)
T1a 21 (4) 0
T1b 48 (9) 0
T2 125 (23) 0 N/A
T3 243 (44) 0
T4a 93 (17) 0
T4b 8 (1) 0
pN stage
a
N0 241 (44) 60 (100)
N1 131 (24) 0
N2 97 (18) 0 N/A
N3a 59 (11) 0
N3b 21 (4) 0
Extent of surgical lymphadenectomy
D1 20 (4) 1 (2)
D2 513 (93) 57 (95) 0.72
c
D3 16 (3) 2 (3)
Number of positive LN
(for XN1; mean, IQR)
3.0 (1–8) 0 (0) N/A
Number of LN examined
(mean, IQR)
23 (15–29) 29 (25–32) 0.04
d
Pathologic treatment effect
(mean %, IQR)
45 (10–95) 100 N/A
Abbreviations: IQR¼interquartile range; LN¼lymph node; N/A¼not applicable
(no statistical analysis performed, as differences are defined by subgroup
stratification); pCR¼pathologic complete response.
aAJCC 7th edn, 2010.
bT0N1
(n¼9) and T0N2 (n¼2) – 1 patient has recurred after a median follow-up of 17
months.
cw
2 text.
dWilcoxon rank sum test with continuity correction. Bold values
indicate significant differences.
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Figure 2 Kaplan–Meier estimates of overall (A), disease-specific (B),
and recurrence-free (C) survival stratified by pathologic complete
response (pCR) vs non-pathologic complete response (non-pCR).
Statistical comparisons between pCR and non-pCR groups were
determined using the log-rank test.
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tive therapy is likely to be distinct from tumours that did not
achieve a pCR (Ajani, 2005; Berger et al, 2005) and is reflected in
RFS and OS. As demonstrated in other malignancies (Wolmark
et al, 2001; Berger et al, 2005; Mamon et al, 2005; Rohatgi et al,
2005; Chen et al, 2007; Chao et al, 2009; Donahue et al, 2009;
Adams et al, 2010; Maas et al, 2010; Park et al, 2010), patients
with gastric/GEJ adenocarcinoma who achieve a pCR following
preoperative therapy have significant improvements in 5-year
OS (60 vs 35%), DSS (67 vs 43%), and RFS (69 vs 45%) when
compared with the group who did not achieve a pCR. However,
despite achieving a pCR, we noted a significant risk of recurrence
in this cohort of patients. Specifically, as shown in Figure 3, there
are no differences in the probability of recurrence between the pCR
and posttreatment stage I and II patients. The distribution of local/
regional (43%) vs distant recurrence (57%) in the pCR and non-
pCR groups is identical. However, there is a significantly higher
rate of CNS first recurrences in the pCR (36%) compared with the
non-pCR (4%) cohort. The increased risk of developing CNS
metastases in patients achieving a pCR is likely due to diminished
penetration of the CNS by all of the chemotherapeutic agents in the
treatment of gastric/GEJ cancer (Chabner and Longo, 2011). Non-
pCR patients, in contrast, are more likely to have persistent
micrometastatic disease in systemic circulation, and are therefore
more likely to have a non-CNS site of first recurrence. Although
CNS recurrences may be more prevalent in patients with
prolonged survival, we would highlight that in our cohort, three
of the five CNS recurrences in the pCR group developed recurrence
early (i.e., o13 months) in their postoperative period, making
our findings more noteworthy. It is well established that CNS
metastases occur in B50% of patients with locally advanced non-
small-cell lung cancer (NSCLC) (Mamon et al, 2005). In patients
with NSCLC treated with preoperative chemoradiation that have a
pCR at the time of resection, there remains a 43% rate of CNS
metastases as the site of first failure, which represents 71% of all
isolated recurrences (Chen et al, 2007). This observation has
led to the use of prophylactic cranial irradiation in patients with
stage III NSCLC treated with preoperative chemoradiotherapy and
curative surgery, a strategy that has significantly reduced
the risk of CNS metastases (18.0 vs 7.7%, unadjusted odds
ratio¼2.52, P¼0.004). However, this strategy has not improved
OS or DFS (Gore et al, 2011). The rate of CNS recurrence in NSCLC
is substantially higher than the 8% rate of CNS as the site of first
failure in patients with gastric/GEJ adenocarcinoma who achieved
a pCR following preoperative therapy, suggesting a limited value of
prophylactic whole brain radiation in this select population.
Interestingly, patients with a pCR had higher numbers of LNs
examined in the pathologic specimen when compared with
non-pCR patients (29 vs 23). In rectal cancer, it is suggested that
interactions between tumour and host immune cells may be
different between pCR and non-pCR tumours (Ogino et al, 2010).
Increased LN count, and in particular increased negative LN count,
has been found to be associated with increased survival in
colorectal cancer (Chang et al, 2007). Patients who achieve a pCR
may elicit a stronger immune response, resulting in more
numerous and larger regional LN, suggesting a possible biologic/
immunologic difference in the host response to these tumours
(Johnson et al, 2006; Ogino et al, 2010). The low frequency of pCR
and varied overall histologic response rates to preoperative
therapy highlight the importance of ongoing research to identify
response to therapy early. We and others have examined FDG-
PET/CT for this purpose (Lordick et al, 2007; Shah, 2007; Ott et al,
2008; Wieder and Weber, 2009). A presently accruing study at our
institution is studying the ability of FDG-PET to discriminate
responders vs non-responders to preoperative chemotherapy for
locally advanced gastric cancer and to salvage non-responding
patients with alternate chemotherapy (Shah, 2011).
This retrospective evaluation reflects the current multidisciplin-
ary approach to patients with gastric cancer in which proximal
gastric tumours (Siewert type II or III) may receive either
chemotherapy alone or combined modality chemoradiation before
surgical resection. Our data are not intended to compare and
contrast the merits of these two distinct treatment approaches, but
rather are focused on the risk and pattern of recurrence of patients
who achieve a significant and complete pathologic response to
preoperative therapy. Notably, we did not observe a difference in
recurrence rate between those receiving chemoradiotherapy (26%)
and those receiving chemotherapy alone (15%). This may, in part,
Table 3 Timing and patterns of recurrence in patients undergoing
preoperative chemotherapy±radiation therapy for gastric and gastro-
oesophageal junction adenocarcinoma, followed by R0 resection
Number (%)
Variable
Non-pCR
patients
(n¼549)
pCR
patients
(n¼60) P-value
Recurrence
Yes 242 (44) 14 (23) —
Probability of recurrence
1 year 28% 12%
3 years 46% 27% 0.01
a
5 years 51% 27%
First recurrence location
b
Local/regional 95 (43) 6 (43) 1.00
c
Distant 128 (57) 8 (57)
CNS as site of first recurrence 10 (4) 5 (36) 0.01
c
Abbreviations: CNS¼central nervous system; pCR¼pathologic complete response.
aLog-rank test.
bRecurrence location information available in 223 out of 242 patients
(92%) that recurred in the non-pCR patient group.
cw
2 test. Bold values indicate
significant differences.
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Figure 3 Cumulative incidences and probabilities of recurrence by stage
(treating death from other causes as a competing risk) in patients
undergoing preoperative chemotherapy±radiation therapy for gastric and
gastrooesophageal junction adenocarcinoma, followed by R0 resection.
Abbreviations: pCR¼pathologic complete response, non-pCR¼non-
pathologic complete response.
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sbe due to the low overall rate of pCR to chemotherapy alone (4%),
corresponding to our limited statistical power to compare these
two groups.
We acknowledge that our observations are based on a small
number of total events (i.e., 14 recurrences in 60 pCR patients,
with 5 CNS recurrences). However, to our knowledge this
represents the largest reported series describing patients with a
pCR after preoperative treatment and surgical resection in gastric/
GEJ adenocarcinoma. All of the patients with CNS metastases
presented with symptomatic seizures or neurologic symptoms.
Early detection of brain metastases may identify these patients
before they experience seizures or symptoms and allow for early
treatment (stereotactic RT and/or surgery). These data support
having an increased awareness of the risk of the CNS as the first
site of recurrence in this cohort of patients. Considering that all
CNS metastases developed within 2 years of follow-up (range 5–24
months), selective surveillance brain imaging (contrast enhanced
CT or MRI) to identify CNS disease before the onset of symp-
toms during the first 2 years of follow-up would be reasonable.
Additionally, we noted that despite achieving a pCR, there was a
43% incidence of local/regional recurrence. Four patients (7% of
all pCR patients and 29% of all pCR recurrences) developed a local
recurrence as the site of first recurrence. Thus, pCR does not
obviate the need for continued local–regional surveillance of this
patient cohort.
In summary, pCR following preoperative chemotherapy±RT
followed by surgical resection for gastric/GEJ adenocarcinoma
occurs in a minority of patients. When compared with non-pCR
patients, a pCR results in improved survival; however, there
remains a significant rate of recurrence. Patients that achieve a
pCR after preoperative therapy have a similar risk of recurrence to
posttreatment pathological stage I and II tumours. In addition,
there is a significantly higher incidence of symptomatic CNS first
recurrences in pCR patients. These findings have important
clinical implications: care providers should be cognizant of the
risk of symptomatic CNS recurrences in this select cohort of
patients and should consider selective brain imaging for early
identification and treatment of CNS metastases.
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